{
    "nctId": "NCT05779566",
    "briefTitle": "Evaluation of the Functional/Emotional Life Characteristics of Ongoing EAT in BC Patients With Reduced BMD",
    "officialTitle": "Exploratory Evaluation of the Functional/Emotional Life Characteristics During the First Year of Ongoing Endocrine Adjuvant Treatment With Aromatase Inhibitors in Breast Cancer Patients With Reduced Bone Mineral Density",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Cancer, Osteopenia",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 82,
    "primaryOutcomeMeasure": "Bone mineral density (BMD)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Before patient registration, written informed consent must be given according to national and local regulations.\n* Participants have had histologically proven stage I-III breast cancer undergoing endocrine treatment (with or without prior chemotherapy) no more than 12 months prior to randomization.\n* Be between 18 and 75 years of age.\n* Have increased life expectancy beyond the initial 3 months post-treatment initiation.\n* Have the ability to understand protocol, participate in testing and willingness to sign a written informed consent.\n* Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.\n\nExclusion Criteria:\n\n* Patients already diagnosed with Osteopenia/Osteoporosis and already receiving BMD treatment (bisphosphonates or denosumab)\n* Patients already diagnosed with osteopenia/osteoporosis who have already suffered a bone event related to decreased BMD\n* Patients that are not willing to sign an informed consent form",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}